Suddenly, Wegovy sales are disappointing

Novo Nordisk, a leading company in the obesity drug market, has revised its profit outlook for the year due to weaker-than-expected sales of its weight loss drug Wegovy. The company’s shares fell following the announcement. Novo’s second-quarter profit also missed expectations, raising concerns about its dominance in the obesity drug market. Despite competition from US rival Eli Lilly, Novo’s CEO downplayed the impact on sales. Novo will continue to limit supplies of the lowest dose of Wegovy to ensure ongoing treatment for patients. The company plans to increase its production capacity to meet growing demand.